Objective: To investigate the expression of galectin-3 (Gal-3) in prolactinomas.
Methods: Expressions of Gal-3 were evaluated by immunohistochemistry using polyclonal antibody in 16 invasive prolactinomas and 16 prolactinomas.
Results: Gal-3 was expressed both in invasive prolactinomas and noninvasive prolactinomas while significantly higher expression seen in the invasive prolactinomas (P < 0.05).
Conclusion: Gal-3 expression may be used as a useful indicator to determine the invasiveness and prognosis of prolactinomas.